Life-threatening infection after marrow transplantation

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Pneumonias due to Pneumocystis carinii, cytomegalovirus, Candida, or Aspergillus are associated with high mortality rates after blood and marrow transplantation despite treatment. Attention has been directed at prophylactic strategies to decrease the incidence of these infections. These approaches represent the major advances in management of life-threatening infection, and have led to improved survival after transplantation. Prophylactic trimethoprim-sulfamethoxazole for Pneumocystis carinii is inexpensive, easy to administer, and is one of the best examples of effective prevention of life-threatening pneumonia in marrow transplantation. Dapsone appears to be an acceptable alternative to patients unable to tolerate this combination of agents. Several strategies are effective in decreasing the incidence of cytomegalovirus pneumonia in high-risk groups, such as allogeneic marrow recipients. Among these approaches are the use of seronegative or leukocyte-depleted blood products for seronegative marrow recipients, and high-dose acyclovir for seropositive recipients. Additionally, recent studies demonstrate the value of early treatment with ganciclovir for recipients with viremia or asymptomatic positive vital culture from bronchoalveolar lavage. Imidazoles, such as fluconazole, reduce the incidence of candidiasis; however, prevention of Aspergillus infections remains a challenge. Thus, chemoprophylaxis may prevent several common infectious causes of pneumonia after blood and marrow transplantation. Challenges remain, such as defining optimal drug dosing, selection of patients, and control of invasive fungal infections.

Original languageEnglish (US)
Pages (from-to)379-384
Number of pages6
JournalSeminars in Respiratory and Critical Care Medicine
Volume17
Issue number5
StatePublished - Sep 1 1996

Fingerprint

Transplantation
Bone Marrow
Pneumonia
Pneumocystis carinii
Infection
Aspergillus
Cytomegalovirus
Incidence
Imidazoles
Dapsone
Ganciclovir
Acyclovir
Fluconazole
Candidiasis
Viremia
Sulfamethoxazole Drug Combination Trimethoprim
Chemoprevention
Bronchoalveolar Lavage
Candida
Patient Selection

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Life-threatening infection after marrow transplantation. / Reed, Elizabeth C.

In: Seminars in Respiratory and Critical Care Medicine, Vol. 17, No. 5, 01.09.1996, p. 379-384.

Research output: Contribution to journalArticle

@article{908135fc22d14caeb9bd78a19cb040e4,
title = "Life-threatening infection after marrow transplantation",
abstract = "Pneumonias due to Pneumocystis carinii, cytomegalovirus, Candida, or Aspergillus are associated with high mortality rates after blood and marrow transplantation despite treatment. Attention has been directed at prophylactic strategies to decrease the incidence of these infections. These approaches represent the major advances in management of life-threatening infection, and have led to improved survival after transplantation. Prophylactic trimethoprim-sulfamethoxazole for Pneumocystis carinii is inexpensive, easy to administer, and is one of the best examples of effective prevention of life-threatening pneumonia in marrow transplantation. Dapsone appears to be an acceptable alternative to patients unable to tolerate this combination of agents. Several strategies are effective in decreasing the incidence of cytomegalovirus pneumonia in high-risk groups, such as allogeneic marrow recipients. Among these approaches are the use of seronegative or leukocyte-depleted blood products for seronegative marrow recipients, and high-dose acyclovir for seropositive recipients. Additionally, recent studies demonstrate the value of early treatment with ganciclovir for recipients with viremia or asymptomatic positive vital culture from bronchoalveolar lavage. Imidazoles, such as fluconazole, reduce the incidence of candidiasis; however, prevention of Aspergillus infections remains a challenge. Thus, chemoprophylaxis may prevent several common infectious causes of pneumonia after blood and marrow transplantation. Challenges remain, such as defining optimal drug dosing, selection of patients, and control of invasive fungal infections.",
author = "Reed, {Elizabeth C.}",
year = "1996",
month = "9",
day = "1",
language = "English (US)",
volume = "17",
pages = "379--384",
journal = "Seminars in Respiratory and Critical Care Medicine",
issn = "1069-3424",
publisher = "Thieme Medical Publishers",
number = "5",

}

TY - JOUR

T1 - Life-threatening infection after marrow transplantation

AU - Reed, Elizabeth C.

PY - 1996/9/1

Y1 - 1996/9/1

N2 - Pneumonias due to Pneumocystis carinii, cytomegalovirus, Candida, or Aspergillus are associated with high mortality rates after blood and marrow transplantation despite treatment. Attention has been directed at prophylactic strategies to decrease the incidence of these infections. These approaches represent the major advances in management of life-threatening infection, and have led to improved survival after transplantation. Prophylactic trimethoprim-sulfamethoxazole for Pneumocystis carinii is inexpensive, easy to administer, and is one of the best examples of effective prevention of life-threatening pneumonia in marrow transplantation. Dapsone appears to be an acceptable alternative to patients unable to tolerate this combination of agents. Several strategies are effective in decreasing the incidence of cytomegalovirus pneumonia in high-risk groups, such as allogeneic marrow recipients. Among these approaches are the use of seronegative or leukocyte-depleted blood products for seronegative marrow recipients, and high-dose acyclovir for seropositive recipients. Additionally, recent studies demonstrate the value of early treatment with ganciclovir for recipients with viremia or asymptomatic positive vital culture from bronchoalveolar lavage. Imidazoles, such as fluconazole, reduce the incidence of candidiasis; however, prevention of Aspergillus infections remains a challenge. Thus, chemoprophylaxis may prevent several common infectious causes of pneumonia after blood and marrow transplantation. Challenges remain, such as defining optimal drug dosing, selection of patients, and control of invasive fungal infections.

AB - Pneumonias due to Pneumocystis carinii, cytomegalovirus, Candida, or Aspergillus are associated with high mortality rates after blood and marrow transplantation despite treatment. Attention has been directed at prophylactic strategies to decrease the incidence of these infections. These approaches represent the major advances in management of life-threatening infection, and have led to improved survival after transplantation. Prophylactic trimethoprim-sulfamethoxazole for Pneumocystis carinii is inexpensive, easy to administer, and is one of the best examples of effective prevention of life-threatening pneumonia in marrow transplantation. Dapsone appears to be an acceptable alternative to patients unable to tolerate this combination of agents. Several strategies are effective in decreasing the incidence of cytomegalovirus pneumonia in high-risk groups, such as allogeneic marrow recipients. Among these approaches are the use of seronegative or leukocyte-depleted blood products for seronegative marrow recipients, and high-dose acyclovir for seropositive recipients. Additionally, recent studies demonstrate the value of early treatment with ganciclovir for recipients with viremia or asymptomatic positive vital culture from bronchoalveolar lavage. Imidazoles, such as fluconazole, reduce the incidence of candidiasis; however, prevention of Aspergillus infections remains a challenge. Thus, chemoprophylaxis may prevent several common infectious causes of pneumonia after blood and marrow transplantation. Challenges remain, such as defining optimal drug dosing, selection of patients, and control of invasive fungal infections.

UR - http://www.scopus.com/inward/record.url?scp=0029850705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029850705&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029850705

VL - 17

SP - 379

EP - 384

JO - Seminars in Respiratory and Critical Care Medicine

JF - Seminars in Respiratory and Critical Care Medicine

SN - 1069-3424

IS - 5

ER -